Akston Biosciences, a United States-based company that deals with insulin engineering, has collaborated with LakePharma, a United States-based CRDMO serving the biotechnology community, to produce commercial quantities of Akston's adjuvated COVID-19 vaccine candidate, AKS-452, it was reported on Tuesday.
The vaccine candidate is scheduled to commence phase 1/2 clinical testing later this month.
AKS-452 is a COVID-19-specific Fc fusion protein vaccine that is in commercial development and is designed to induce or boost a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain of the novel SARS-CoV-2 coronavirus spike protein. It is shelf-stable for weeks at up to 37 degrees Celsius and is engineered to use conventional antibody manufacturing techniques.
Ascletis Pharma's IND application for COVID-19 drug ASC11 receives US FDA approval
STORM Therapeutics doses first patient with STC-15
bit.bio Expands Its Portfolio with Three New Human Cell Products
Iktos Partners with Medicines for Malaria Venture in Anti-Malarial Drug Discovery
Sintalica Bioscience Announces Key Approval Milestones from the Italian Health Authority
RSV Cases Rise Again, with 90% of US ER Physicians Treating a Case in Past Two Weeks
Alcami completes Phase II of Amherst cGMP biostorage facility